A total of 26,633 patients were excluded due to the delayed start of adjuvant chemotherapy beyond 90 days, because they received less than 50% of the planned chemotherapy cycles or treatment doses, or because they had HER2 + BC or an unknown status of HER2, but treated were with trastuzumab. Here, ERBB2 is linked to breast cancer.